By Daniella Parra
Lisata Therapeutics (Nasdaq: LSTA) said a study led by The University of Kansas Cancer Center, is testing Lisata’s investigational peptide certepetide with FOLFIRINOX-based therapies in pancreatic, colon, and appendiceal cancers.
In 35 PDAC patients treated, the combination was safe with no serious adverse events linked to certepetide and of 10 patients completing pre-surgical therapy, 50% achieved no residual cancer with 70% having a partial pathologic response, they said.
“The initial results from the CENDIFOX trial are very encouraging, showing that certepetide can enhance the effectiveness of standard-of-care chemotherapy in pancreatic cancer,” stated Kristen K. Buck, M.D., Executive Vice President of Research and Development and Chief Medical Officer of Lisata. “We believe these findings are a significant step forward in a disease with few beneficial treatment options. ”
READ MORE
New Speakers Announced: 5th Palm Beach CorpGov Forum | Preview Panelists & Topics
Never Miss our Weekly Highlights HERE
